Ironwood Pharmaceuticals and Forest Laboratories, Inc. to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012
Published: May 14, 2012
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will present linaclotide-related data in one oral presentation and 16 poster presentations during Digestive Disease Week (DDW) 2012 being held in San Diego, May 19 through May 22, 2012. Linaclotide is an investigational guanylate cyclase type-C agonist (GCCA) for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.